Although there have been advances in multimodal treatment options for oral squamous cell carcinoma (OSCC) in the past 20 years ([@bib39]), the overall prognosis of this specific cancer type has not improved as substantially as for other malignancies ([@bib19]). This observation serves as a call to action to critically analyse the current diagnostic and therapeutic regime by considering all relevant biological tumour characteristics.

Prognostic assessment and therapeutic decision-making depend on TNM staging and histological grading. The preoperative staging process includes radiological imaging and diagnostic incision biopsies. Small OSCC (T1 and T2) are commonly treated by surgical tumour resection ([@bib48]).

For these reasons, OSCC patients are commonly subjected to two invasive surgical procedures (the diagnostic incision biopsy and the later tumour resection) with a time interval of some days or weeks between the two procedures ([@bib48]).

Oral surgery, such as diagnostic incision biopsies, represents local tissue trauma leading to wound-healing responses. A recent study showed that OSCC patients undergoing preoperative oral surgery exhibited a significant increase in lymph node metastases (pN+) and distant metastases (cM1) and a significantly decreased 5-year survival rate ([@bib44]) when compared with patients who did not undergo preoperative oral surgery. This report and other studies ([@bib37]; [@bib43]) suggested a correlation between local tissue trauma and increased malignancy in oral cancer.

These suggestions are not new; a possible negative effect of tumour biopsies has been discussed in the literature for years. A report from 1978 postulated that tumour surgery had biological consequences and even that the surgical procedures themselves could provoke the exacerbation of metastases ([@bib23]). Another old study stated that cytoreductive surgery in testicular cancer was followed by a dramatic exacerbation of the disease in some cases ([@bib28]).

Several further reports in the older literature showed a negative influence of surgical intervention on tumour progression ([@bib21]; [@bib6]), but no biological explanations for the observed effects were given.

Recent findings from an animal study supported these suggestions. Biopsies were shown to significantly increase the frequency of lung metastases by 3--5-fold ([@bib16]). In addition, a significant increase in primary tumour growth was observed in mice that underwent biopsies ([@bib16]). Immunohistochemically, an increased number of inflammatory cells was detected at the primary tumour site and in lung metastases ([@bib16]). This finding indicates the presence of a possible inflammatory reaction after tumour biopsies.

Surgical interventions lead to a wound-healing response accompanied by a number of immunological reactions that have recently been elucidated. The recruitment of inflammatory cells and repolarisation of invading and resident tissue macrophages towards the M2 type is the dominant immunological reaction ([@bib31]; [@bib33]; [@bib30]). M1-type macrophages are responsible for the elimination of pathogens, tissue destruction and tumour resistance ([@bib31]; [@bib42]; [@bib30]). In contrast, M2-type macrophages have immunoregulatory features and are associated with wound-healing, tissue remodelling, angiogenesis and tumour progression ([@bib31]; [@bib8]; [@bib15]; [@bib26]; [@bib34]; [@bib12]; [@bib27]; [@bib42]; [@bib30]; [@bib46]). Results from our group showed that increased M2 macrophage polarisation in the epithelial compartment of OSCC patients is correlated with the occurrence of locoregional lymph node metastases ([@bib46]). Furthermore, an increased malignant behaviour of the tumours was associated with a shift towards M2 polarisation in the regional lymph nodes ([@bib47]).

The preoperative diagnostic tumour biopsy---a procedure that is highly relevant for treatment planning---also represents local tissue trauma that can lead to immunological alterations. Therefore, a possible negative influence of biopsies on tumour immunobiology might be associated with a biopsy-induced shift in macrophage polarisation towards the M2 type.

To date, no studies have analysed the possible influence of tumour biopsies on macrophage polarisation in human cancers. Therefore, the aim of this study was to clarify whether macrophage polarisation in diagnostic biopsies of small (pT1 and pT2) primary OSCC differed from that found in definitive tumour resections. To this end, immunohistochemical analyses of the specimens were performed using a computer-assisted quantitative cell counting method.

Materials and Methods
=====================

Patients and tissue harvesting
------------------------------

Biopsy and tumour specimens from 34 patients histologically diagnosed with primary OSCC were analysed in this retrospective study. Tumour resection specimens from 34 patients and biopsy specimens from 25 patients were included in this study. The biopsy specimens from nine cases were excluded because they were obtained at other institutions and were not available for analysis or contained only small carcinoma fractions not suitable for analysis. Because we counted macrophage infiltration in at least 1.1 mm^2^ of carcinoma tissue, specimens with carcinoma fractions smaller than 1 mm^2^ were considered to be not suitable for analysis and were excluded. All included patients were treated in 2011 at the Department of Oral and Maxillofacial Surgery of the University Hospital Erlangen. The study protocol was approved by the ethical committee of the University of Erlangen-Nuremberg (Ref.-No. 45_12 Bc). The specimens used in this study were obtained from tissue samples collected for routine histopathological diagnosis. Each included specimen was judged by a pathologist to be a representative squamous cell carcinoma. In addition to the main diagnosis of OSCC, the following inclusion criteria were defined: pT1 and pT2 tumours, no restrictions in the grading of the tumour, no adjuvant preoperative radio- or chemotherapy and no organ metastasis at the time of diagnosis.

Only OSCC specimens from patients with pT1 and pT2 were considered because the tumours of these patients were characterised by a better resectability and prognosis compared with the larger pT3 and pT4 tumours ([@bib36]). Furthermore, T4 tumours might have a special immunological microenvironment because of their direct contact with bone marrow stem cells ([@bib7]).

Patients with former radio- or chemotherapy and pT3 and pT4 tumours were excluded. No study-related changes in the patients\' treatments took place.

The patient cohort (*n*=34) consisted of 11 patients with a tumour of the tongue, 11 patients with a tumour of the floor of the mouth, 8 with a tumour of the alveolar crest, 3 with a tumour of the palate and 1 with a tumour of the cheek.

The average age of the patients (23 males and 11 females) was 63 years. The pathohistological classified N-status was N0 in 19 cases and N+ in 15 cases. The histological grading was G1 in 2 cases, G2 in 26 cases and G3 in 6 cases. None of the patients in our cohort had distant metastases.

Immunohistochemical staining
----------------------------

The formalin-fixed, paraffin-embedded tissue samples were sliced in consecutive, 2-μm thick sections with a rotation microtome (Leica, Nussloch, Germany), then dewaxed in xylole and rehydrated in graded propanol before immunohistochemical staining. The immunohistochemical staining was performed with the LSAB (labelled streptavidin-biotin) method and an automated staining device (Autostainer Plus, Dako Cytomation, Hamburg, Germany). The staining kit (Dako Real, Cat. K5001, Dako Cytomation) was used according to the manufacturer\'s instructions. Proteins were detected by incubating tissues in the autostainer (21 °C, 30 min) with specific antibodies.

The following primary antibodies were used: anti-CD11c (ab52632, clone EP1347y, Abcam, Cambridge, UK), anti-CD68 (11081401, clone KP1, Dako), anti-CD163 (MAB1652, clone K20-T, Abnova, Taipei City, Taiwan) and anti-MRC1 (H00004360-1102, clone 5C11, Abnova).

Biotinylated immunoglobulins were used as the secondary antibody for all samples. DAB+ solution (Dako Cytomation) was used as the chromogen. Hematoxylin (Dako Cytomation) was applied for counterstaining of the nuclei. Two consecutive tissue samples were processed per immunohistochemical stain, with one serving as a negative control in each case (identical treatment except for replacement of the primary antibody with an IgG-isotype of the primary antibody). An appropriate positive control was included in each series.

Quantitative immunohistochemical analysis
-----------------------------------------

The tumour and biopsy sections were completely scanned and digitised using the method of 'whole-slide imaging\'. The scanning procedure was performed in cooperation with the Institute of Pathology of the University of Erlangen using a Zeiss MIRAX MIDI Scanner (Zeiss, Jena, Germany). All samples were analysed on a computer (Panoramic MIRAX viewer, Zeiss). Quality controls were performed under a bright-field microscope (Zeiss Axioskop and Axiocam 5, at × 100--400 magnification). H&E-stained sections of all samples were examined to ensure that all samples contained representative squamous cell carcinoma tissue.

For each sample, three visual fields showing the highest infiltration rate of positive cells were selected ([Figure 1](#fig1){ref-type="fig"}) using multi-monitor virtual microscopy (Panoramic MIRAX viewer, Zeiss). The complete area of all three visual fields of one specimen was between 1.1 and 1.5 mm^2^.

The images showing the visual fields were imported into Biomas (modular systems of applied biology, MSAB, Erlangen, Germany) for cell counting. Two regions of interest were defined in the visual fields using the Biomas software (Erlangen, Germany): the epithelial tumour fraction and the tumour stroma.

A quantitative analysis was performed to determine the numbers of infiltrating CD11c-, CD68-, CD163- and MRC1-positive cells in the epithelial tumour fraction and the surrounding stroma. All positive cells in the aforementioned compartments were manually counted. Cell density per mm^2^ was automatically calculated by the Biomas software. Only cells with a monocytoid/macrophage-like morphology were counted. Cell counting was performed in a blinded manner by six research fellows familiar with tissue morphology analysis and immunohistochemical methods. In case of a discrepancy, the analyses were discussed with the authors.

Statistical analysis
--------------------

To analyse the immunohistochemical staining and spatial expression patterns, the cell count per mm^2^ was determined as the number of positive cells per mm^2^ of the specimen. Multiple measurements were pooled for each sample group before analysis. The results are expressed as the median, the interquartile range, s.d. and range. Box plot diagrams represent the median, the interquartile range, minimum (Min) and maximum (Max).

Two-sided, adjusted *P*-values⩽0.05 were considered to be significant. The analyses were performed using an ANOVA test with SPSS 21 for Mac OS (IBM Inc, New York, NY, USA).

Results
=======

General morphological considerations
------------------------------------

All of the specimens were analysed using a virtual microscope system. In the tumour resection specimens, all analysed markers showed significantly (*P*\<0.05) higher expression in the stroma compared with the epithelial tumour fraction. In the biopsy samples, all stained markers with the exception of CD11c displayed a significantly (*P*\<0.05) higher number of positive cells in the stroma compared with the epithelial tumour compartment.

The stroma of the invasive margin exhibited the highest macrophage infiltration in 12 of the cases ([Figure 1](#fig1){ref-type="fig"}). However, the hot spots of macrophage infiltration were randomly distributed in the majority of cases. For each marker, three regions of the highest macrophage infiltration density were selected for cell counting. In eight cases, the preoperative biopsy site was contained by the investigated sections of tumour resection specimens. These areas were excluded from our analyses.

Numerous CD68-positive cells were observed in all analysed cases. A cytoplasmatic expression pattern was found. The stained cells were predominantly round, but some were spindle shaped ([Figure 2](#fig2){ref-type="fig"}). In most cases, pale staining of epithelial cells was detectable in addition to distinct staining of the macrophages. This epithelial reactivity included the tumour cells as well as the normal epithelium.

The CD11c-expressing cells were stained both in the cytoplasm and at membrane-bound locations and showed a round shape ([Figure 2](#fig2){ref-type="fig"}).

Expression of the M2 macrophage marker CD163 was observed in the cytoplasm and bound to the membrane. Most of the stained cells were spindle shaped ([Figure 2](#fig2){ref-type="fig"}).

Macrophage marker expression in biopsy and tumour specimens
-----------------------------------------------------------

The mean time between preoperative diagnostic incision biopsy and tumour resection was 15 days (s.d. 9.6) ([Table 1](#tbl1){ref-type="table"}), with a range from 2 to 34 days. The time interval between biopsy and tumour resection did not correlate with the difference in macrophage marker expression between biopsies and tumour resections ([Table 1](#tbl1){ref-type="table"}).

In the epithelial compartment of tumour specimens, the CD163 cell count (M2 macrophages) was significantly higher (median value of 104 cells per mm^2^) than in the biopsy specimens (median value of 56 cells per mm^2^) (*P*=0.034) ([Table 2](#tbl2){ref-type="table"}, [Figure 3B](#fig3){ref-type="fig"}).

In analogy to the epithelial compartment, CD163 expression in the stroma of the tumour samples (median value of 442 cells per mm^2^) was significantly higher than in the biopsy specimens (median value of 249 cells per mm^2^) (*P*=0.003) ([Table 2](#tbl2){ref-type="table"}, [Figure 3C](#fig3){ref-type="fig"}).

The same relationship was apparent when CD163 expression in the whole analysed specimen area (epithelial+stroma) was taken into consideration. The CD163 expression was significantly higher in the tumour samples (*P*=0.00002), with a median value of 168 cells per mm^2^ in biopsy specimens compared with 316 cells per mm^2^ in tumour samples ([Table 2](#tbl2){ref-type="table"}, [Figure 3D](#fig3){ref-type="fig"}). The increase in CD163-positive cell infiltration was independent of the time between biopsy and tumour resection ([Table 1](#tbl1){ref-type="table"}). A total of 92% of the patients (22 out of 24) showed an increase in CD163-positive cell infiltration in the tumour resection specimens compared with the biopsies. The mean increase in CD163-positive cell infiltration was 108% ([Table 1](#tbl1){ref-type="table"}).

In addition to CD163, CD11c expression in the stroma compartment was significantly higher (median value of 256 cells per mm^2^) in the tumour resection specimens than in the biopsies (median value of 164 cells per mm^2^) (*P*=0.036) ([Table 2](#tbl2){ref-type="table"}).

There was no significant difference in the expression of other macrophage markers (i.e., CD68 and MRC1) between the tumour and biopsy samples. In summary, the tumour specimens showed significantly increased infiltration of CD163-positive M2 macrophages. This correlation was apparent in all tumour compartments.

Macrophage polarisation in biopsy and tumour specimens
------------------------------------------------------

The ratio between CD163-positive cells (predominantly M2 macrophages) and CD68-positive cells (all macrophages) can be considered as the degree of M2 polarisation. In the epithelial compartment, the CD163/CD68 ratio was significantly higher in tumour samples (median value 0.40) than in biopsies (median value 0.29) (*P*=0.019) ([Table 3](#tbl3){ref-type="table"}, [Figure 4A](#fig4){ref-type="fig"}).

A similar proportion was revealed when the whole analysed area (epithelial+stroma) was taken into consideration. There was a significantly higher ratio in tumour samples (median value 0.64) than in biopsy specimens (median value 0.48) (*P*=0.003) ([Table 3](#tbl3){ref-type="table"}, [Figure 4B](#fig4){ref-type="fig"}).

The ratios of other parameters (such as the CD11c/CD68 ratio) did not differ between biopsy and tumour specimens. In summary, tumour specimens showed a significant increase in M2 polarisation.

Discussion
==========

Value of macrophage polarisation markers
----------------------------------------

Although the biological relevance of macrophage polarisation in tumour progression is undoubted, an accurate characterisation of the available markers is lacking. The detection of M1 and M2 polarised macrophages using the currently available markers remains problematic ([@bib4]; [@bib47]). For this reason, we used macrophage markers frequently described in the literature and successfully used in our previous projects ([@bib46]; [@bib47]). CD68 is the best established generic macrophage marker ([@bib20]; [@bib29]; [@bib26]; [@bib9]). Immune regulatory and tumour-promoting M2 macrophages are commonly identified by staining the CD163 antigen ([@bib2]; [@bib20]; [@bib8]; [@bib13]). Some studies also use MRC1 to detect M2 cells ([@bib2]; [@bib15]; [@bib45]). In contrast, M1 discriminating markers are not as well defined. CD11c staining is most commonly used to visualise human M1 macrophages ([@bib11]; [@bib15]; [@bib9]; [@bib38]).

In addition, the relative proportion of the M1 and M2 markers should also be considered. In analogy to other recent studies dealing with macrophage polarisation in human cancer tissues ([@bib27]; [@bib14]; [@bib18]; [@bib46]), we aimed to analyse the ratios between the stained markers.

Tumour resection specimens show increased M2 polarisation of infiltrating macrophages compared with preoperative biopsies
-------------------------------------------------------------------------------------------------------------------------

In the present study, an increase in M2 polarisation was noted in tumour resection specimens from OSCC compared with samples obtained from preoperative incision biopsies.

CD163 is the most commonly used and best established marker for M2 polarised macrophages ([@bib20]; [@bib8]; [@bib13]). Our data showed a significantly increased infiltration of CD163-positive cells in tumour specimens in all analysed tissue compartments (i.e., epithelial fraction, stroma and whole analysed area) ([Table 2](#tbl2){ref-type="table"}). The CD163/CD68 ratio was used as an indicator of M2 polarisation and was significantly higher in the epithelial fraction and the whole analysed area of the tumour specimens compared with the biopsies ([Table 3](#tbl3){ref-type="table"}). These data indicate a change in the macrophage composition between biopsies and tumour resections towards M2 polarisation. M2 polarisation of macrophages in OSCC was previously shown to be associated with metastatic growth ([@bib46]) and an unfavourable prognosis ([@bib3]).

Expression of CD68, MRC1 and CD11c
----------------------------------

The expression of the generic macrophage marker CD68 did not significantly differ between the biopsy and the tumour resection groups. However, a trend towards increased macrophage infiltration in the tumour resection specimens was observed in the stroma compartment ([Table 2](#tbl2){ref-type="table"}).

The expression of MRC1 did not differ significantly between tumours and biopsies.

In contrast, significantly higher CD11c expression was detected in the stroma fraction of tumour specimens ([Table 2](#tbl2){ref-type="table"}). The absence of an established marker for M1 polarised macrophages is an unsolved problem in macrophage research. Several studies have suggested CD11c as an M1 macrophage marker ([@bib11]; [@bib15]; [@bib9]). However, some authors have also used CD11c as a marker for dendritic cells ([@bib1]). Thus, one fraction of the CD11c-positive cells might represent dendritic cell subsets. One group analysed the gene expression profile of CD11c low and CD11c high macrophages in decidual tissue ([@bib17]) and detected differential gene expression profiles in both subtypes. Interestingly, both cell types expressed pro- and anti-inflammatory cytokines. Therefore, the authors concluded that CD11c-expressing macrophages did not fit into the classical M1--M2 allocation ([@bib17]). Based on the available data, we can conclude that CD11c cannot be considered a specific marker for M1 polarised macrophages. These data also indicated that macrophage polarisation was more complex than a linear spectrum with M1 and M2 representing the extremes. The lack of a reliable M1 marker is a common problem in macrophage research that still needs to be resolved.

M2 polarisation and the risk of lymph node metastases
-----------------------------------------------------

Our previous work showed an association between M2 polarised macrophages in the epithelial fraction of OSCC tissue and the occurrence of lymph node metastases ([@bib46]). The tumour-promoting capabilities of M2 macrophages have been demonstrated *in vitro* and *in vivo* ([@bib5]; [@bib42]; [@bib10]; [@bib3]).

Recent animal studies revealed a correlation between tumour biopsies and an increased local progression and occurrence of metastases ([@bib16]). The authors considered immunological factors to be responsible for this phenomenon and detected an increased infiltration of CD45-positive leukocytes at the biopsy site. However, macrophage polarisation was not examined ([@bib16]). The recent finding that preoperative oral surgery procedures were associated with a worse prognosis and increased risk of developing lymph node metastases in OSCC patients showed that preoperative local tissue trauma influenced tumour biology ([@bib44]). Because the preoperative incision biopsy represents a tissue trauma, a tumour biological effect is to be expected.

Because the local tumour microenvironment was shown to influence the polarisation of TAM, the wound-healing reaction consecutive to tissue trauma might serve as a microenvironmental stimulus that affects macrophage polarisation ([@bib25]).

The presented findings indicate a biopsy-associated shift in macrophage polarisation towards M2. The increased M2 polarisation seems to be independent of the time interval between the biopsy and tumour resection.

Possible mechanisms underlying the biopsy-associated M2 polarisation of macrophages
-----------------------------------------------------------------------------------

Biopsy-induced tissue trauma---as with any other surgical procedure---triggers an acute inflammatory reaction and initiates wound-healing processes ([@bib16]). Initially, tissue damage leads to an acute inflammatory response dominated by M1 macrophages. Later, a shift in macrophage polarisation towards M2 can be observed ([@bib30]). M2 macrophages contribute to tumour progression by secreting pro-angiogenic factors such as vascular endothelial growth factor and extracellular matrix remodelling proteins such as matrix metalloproteases ([@bib30]). In addition, they induce T-cell tolerance by reducing MHCII expression and the secretion of the immunosuppressive cytokines IL-4, IL-10 and TGF-β ([@bib30]).

In the case of a two-step surgical procedure with a long time interval between the biopsy and a definitive tumour resection, a shift towards healing associated with M2 polarisation might negatively influence tumour biology.

Limitations of the study
------------------------

The patient collective (34 tumour resection specimens and 25 biopsy specimens) of this retrospective study was relatively small. No correlation between the duration of the time interval between the biopsy and tumour resection and the increase of M2 polarised macrophages was seen in this study. A larger patient collective could eventually reveal such correlations.

Potential strategies to prevent M2 polarisation in solid tumours
----------------------------------------------------------------

One therapeutic approach targeting possible biopsy-induced M2 polarisation could be the preoperative application of bisphosphonates. The rationale behind this concept is the recently discovered capability of bisphosphonates to repolarise macrophages from a tumour-promoting M2 phenotype to an anti-tumoural M1 phenotype ([@bib40]).

In contrast to high-dose radiotherapy, low-dose irradiation can shift macrophage polarisation towards the anti-tumoural M1 type ([@bib32]). Indeed, 2 Gy of irradiation was able to increase M1 polarisation followed by T-cell recruitment in a tumour xenotransplant mouse model ([@bib22]). Furthermore, irradiation might be capable of inducing an immunostimulatory form of tumour cell death, leading to maturation and activation of antigen presenting cells such as macrophages and dendritic cells ([@bib24]; [@bib41]).

The recently described ability of non-steroidal anti-inflammatory drugs to prevent M2 polarisation ([@bib35]) has potential therapeutic relevance. Treatment with the non-steroidal anti-inflammatory drugs ibuprofen before and after biopsy significantly reduced the number of biopsy-associated lung metastases in mice ([@bib16]).

Conclusion
==========

We propose that preoperative tumour biopsies lead to increased M2 polarisation of macrophages. This polarisation may be associated with accelerated tumour progression in OSCC.

Prospective studies investigating macrophage markers and the prognosis of patients are needed to prove this hypothesis. These studies should aim to determine whether there is a cut-off time point between biopsy and tumour resection at which macrophage polarisation shifts towards the tumour-promoting M2 type.

We thank Luitpold Distel for providing the Biomas analysis software and for assistance with the cell counting procedure. We also thank Carol I. Geppert for assistance with the 'whole-slide imaging\' and the digitalisation of the samples. We thank Susanne Schoenherr and Elke Diebel for technical assistance. We also thank the dental students/research fellows Katharina Schoeps, Katharina Loika, Victoria Stanuch, Carina Pirner, Isabell Konopka and Katharina Kaul for processing the tissue specimens, operating the immunohistochemistry autostainer apparatus and cell counting. This study was financially supported by the foundation 'ELAN Fonds der Universität Erlangen\' (grant to Manuel Weber in 2012).

**Author contributions**

MW formulated the hypothesis, applied for grant support (ELAN-Fonds, University of Erlangen-Nürnberg), initiated and conducted the study, interpreted the data and wrote the manuscript. FW formulated the hypothesis, interpreted the data and contributed relevantly to the manuscript. PM performed the immunohistochemical analyses and the whole-slide imaging of the specimens, helped with cell counting and critically reviewed the manuscript. MB and KA helped validate the markers, contributed to the discussion and critically reviewed the manuscript. FN and RP contributed to the discussion and critically reviewed the manuscript. All authors read and approved the final manuscript.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License

The authors declare no conflict of interest.

![**Virtual microscopy and selection of visual fields.** The figure shows an exemplary virtual microscope slide. A panoramic view is displayed on the left side and a magnification of the indicated region is displayed on the right side. The magnification can vary continuously and is selected on the computer. Three visual fields containing epithelial tumour fractions and stroma were selected for cell counts. The visual fields are indicated in yellow boxes. The specimen is an oral squamous cell carcinoma biopsy stained for CD163-positive cells. A full colour version of this figure is available online at the *British Journal of Cancer* website.](bjc2015212f1){#fig1}

![**Typical expression patterns of the macrophage markers CD68, CD11c, CD163 and MRC1 in a squamous cell carcinoma biopsy.** Exemplary fields of view (original magnification × 40) showing the typical expression pattern of the stained macrophage markers CD68, CD11c, CD163 and MRC1 in biopsy specimens. (**A**) CD68: the marker shows cytoplasmatic staining. The shape of the stained cells includes predominantly round cells (yellow arrow), but some cells also show a spindle shape (red arrow). CD68 is expressed in the epithelial tumour fraction and in the stroma. (**B**) CD11c: the marker shows a cytoplasmatic expression pattern with an accentuation of the plasma membrane. The shape of the stained cells includes predominantly round cells (yellow arrow). CD11c showed the lowest expression levels of all stained macrophage markers. CD11c-expressing cells were found mainly in the tumour stroma and also in the epithelial tumour fraction. (**C**) CD163: the marker shows a cytoplasmatic expression pattern with an accentuation of the plasma membrane. The shape of the stained cells includes predominantly spindle-shaped cells (red arrow). CD163 expression was higher in the stroma than in the epithelial tumour compartment. (**D**) MRC1: the marker shows a cytoplasmatic expression pattern with an accentuation of the plasma membrane. The shape of the stained cells includes predominantly spindle-shaped cells (red arrow). MRC1 expression not only can be found predominantly in the stroma but also in the epithelial tumour fraction. A full colour version of this figure is available online at the *British Journal of Cancer* website.](bjc2015212f2){#fig2}

![**Macrophage cell counts (cells per mm^2^) in biopsy and tumour resection specimens of oral squamous cell carcinomas.** (**A**) The figure shows the expression of the M2 macrophage marker CD163 in biopsy and tumour resection samples from the same patient. The number of CD163-expressing cells in the tumour samples is significantly higher in the epithelial tumour compartment and the stroma. (**B**) The figure shows the median CD163 cell count (cells per mm^2^ specimen area) in the epithelial compartment of the biopsy and tumour specimens. *P*-values generated by the ANOVA test are indicated. A significantly increased count of CD163-positive cells can be found in the epithelial fraction of the tumour specimens. (**C**) The figure shows the median CD163 cell count (cells per mm^2^ specimen area) in the stroma compartment of the biopsy and tumour specimens. *P*-values generated by the ANOVA test are indicated. A significantly increased count of CD163-positive cells can be found in the stroma of tumour specimens. (**D**) The figure shows the median CD163 cell count (cells per mm^2^ specimen area) in the whole analysed area (epithelial+stroma) of the biopsy and tumour specimens. *P*-values generated by the ANOVA test are indicated. A significantly increased count of CD163-positive cells can be found in tumour specimens.](bjc2015212f3){#fig3}

![**Macrophage polarisation in biopsy and tumour resection specimens of oral squamous cell carcinomas.** (**A**) The figure shows the ratio between the CD163 cell count and the CD68 cell count in the epithelial compartment of biopsy and tumour specimens as an indicator of M2 polarisation. *P*-values generated by the ANOVA test are indicated. A significantly increased CD163/CD68 ratio in the tumour samples compared with the biopsy samples is demonstrated. (**B**) The figure shows the ratio between the CD163 cell count and the CD68 cell count in the whole analysed area (epithelial+stroma) of biopsy and tumour specimens as an indicator of M2 polarisation. *P*-values generated by the ANOVA test are indicated. A significantly increased CD163/CD68 ratio in the tumour samples compared with the biopsy samples is demonstrated.](bjc2015212f4){#fig4}

###### Time interval between biopsy and tumour resection and increase im macrophage marker expression

  **Patient**    **Time between biopsy and tumour resection (in days)**   **Increase of CD68 infiltration**   **Increase of CD11c infiltration**   **Increase of CD163 infiltration**   **Increase of MRC1 infiltration**
  ------------- -------------------------------------------------------- ----------------------------------- ------------------------------------ ------------------------------------ -----------------------------------
  1                                        14                                            43%                                 391%                                 141%                                100%
  2                                        6                                            −37%                                 −50%                                 73%                                 −41%
  3                                        12                                            23%                                 105%                                 243%                                244%
  4                                        26                                           n.a.                                 n.a.                                 n.a.                                n.a.
  5                                        2                                             56%                                 −91%                                 245%                                 55%
  6                                        5                                            −24%                                 −63%                                 35%                                  −9%
  7                                        12                                            46%                                 −43%                                 48%                                  38%
  8                                        18                                           −17%                                 −40%                                 62%                                  18%
  9                                        12                                            86%                                 −37%                                 61%                                  30%
  10                                       8                                             23%                                 154%                                 80%                                  44%
  11                                       12                                            −4%                                 −12%                                 22%                                 −13%
  12                                       32                                            76%                                 18%                                  260%                                104%
  13                                       6                                             31%                                 32%                                  112%                                 −3%
  14                                       6                                            −17%                                 −62%                                 39%                                  31%
  15                                       6                                            −14%                                 75%                                  19%                                  13%
  16                                       32                                            50%                                 −27%                                 20%                                 −43%
  17                                       33                                            51%                                 24%                                  18%                                  91%
  18                                       34                                           −13%                                 54%                                  29%                                 −26%
  19                                       13                                           −65%                                1183%                                −100%                                104%
  20                                       13                                            3%                                  101%                                 244%                                 20%
  21                                       14                                            58%                                 56%                                  621%                                277%
  22                                       11                                            −9%                                 87%                                  −26%                                −38%
  23                                       5                                             37%                                 43%                                  63%                                 −22%
  24                                       16                                           168%                                 −5%                                  128%                                 14%
  25                                       18                                            77%                                 181%                                 150%                                106%
  Mean                                     15                                            26%                                 86%                                  108%                                 45%
  *P*-value                                                                             0.264                               0.972                                0.948                                0.713

Table 1 shows the time interval between diagnostic biopsy and tumour resection (in days) and the increase in CD68, CD11c, CD163 and MRC1 infiltration (in %, epithelial+stroma) in tumour resection specimens compared with biopsies. The analysis is not available for patient 4 because of insufficient carcinoma tissue in the tumour resection specimen. Mean values and *P*-values (Pearson correlation: time interval biopsy-tumour resection and increase of macrophage marker infiltration) are shown.

###### Macrophage marker expression (cells per mm^2^) in biopsy and tumour specimens

  **Marker**                   **CD68**   **CD11c**   **CD163**   **MRC1**                    
  --------------------- ----- ---------- ----------- ----------- ---------- ----- ----- ----- -----
  Epithelial fraction    *n*                                                                     
  Biopsy                 25      306         151         114        143      56    73    154   152
  Tumour                 34      266         176         148        134      104   119   179   144
  *P*-value                     0.550       0.949       0.034      0.818                      
  Stroma fraction        *n*                                                                     
  Biopsy                 25      464         306         164        144      249   211   515   366
  Tumour                 34      688         287         256        283      442   232   610   277
  *P*-value                     0.070       0.036       0.003      0.102                      
  Epithelial+stroma      *n*                                                                     
  Biopsy                 25      372         160         168        111      168   92    342   204
  Tumour                 34      486         164         206        189      316   137   387   177
  *P*-value                     0.098       0.087       0.000      0.144                      

Table 2 shows the macrophage cell count (positive cells per mm^2^) in biopsy and tumour specimens. For each marker, the expression in the epithelial tumour fraction, the tumour stroma and the whole analysed area (epithelial+stroma) is presented. Values represent the median, s.d. and *P*-value (ANOVA).

###### Ratio of macrophage marker expression in biopsy and tumour tissue

                     **CD163/CD68 epithelial**   **CD163/CD68 stroma**   **CD163/CD68 epithelial+stroma**                
  ----------- ----- --------------------------- ----------------------- ---------------------------------- ------ ------ ------
  Tissue       *n*                                                                                                          
  Biopsy       25              0.29                      0.25                          0.54                 0.50   0.48   0.23
  Tumour       34              0.40                      0.25                          0.74                 0.30   0.64   0.27
  *P*-value                    0.019                     0.509                        0.003                              

                      **CD11c/CD68 epithelial**   **CD11c/CD68 stroma**   **CD11c/CD68 epithelial+stroma**                
  ----------- ------ --------------------------- ----------------------- ---------------------------------- ------ ------ ------
  Tissue       *n*                                                                                                           
  Biopsy       *25*             0.47                      0.43                          0.37                 0.26   0.45   0.28
  Tumour       *34*             0.53                      0.28                          0.36                 0.48   0.38   0.38
  *P-*value                     0.632                     0.236                        0.349                              

Table 3 shows the ratio of macrophage marker expression in biopsy and tumour specimens. Values represent the median, s.d. and *P*-value (ANOVA).
